---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-107209"
form_type: "8-K"
ticker: "QURE"
cik: "0001590560"
company_name: "uniQure N.V."
filed_at: "2023-10-05T23:59:59+00:00"
generated_at: "2026-06-10T03:58:55.984131+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# uniQure cuts 28% of workforce, discontinues over half of R&D projects to extend cash runway to Q2 2027

## Summary
- Workforce reduction of 114 positions (28% of workforce not committed to HEMGENIX) with $180M cost savings over three years.
- Discontinuation of more than half of research projects including AMT-210 for Parkinson's disease.
- Cash runway extended into Q2 2027; $628.6M cash at June 30, 2023 plus $100M milestone from CSL Behring.
- CSO Ricardo Dolmetsch departs; Rich Porter named Chief Business and Scientific Officer effective Oct 5, 2023.
- Clinical focus on AMT-130 (Huntington's), AMT-260 (epilepsy), AMT-162 (SOD1-ALS), and AMT-191 (Fabry).

## SEC filing metadata
- accession: 0001104659-23-107209
- form_type: 8-K
- ticker: QURE
- cik: 0001590560
- company_name: uniQure N.V.
- filed_at: 2023-10-05T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.05, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590560/000110465923107209/0001104659-23-107209-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590560/000110465923107209/tm2327835d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-107209
- JSON: https://secwatch.observer/filing/0001104659-23-107209.json
- Plain text: https://secwatch.observer/filing/0001104659-23-107209.txt

## Key facts
- Executive change
  Ricardo Dolmetsch was terminated as Chief Scientific Officer at uniQure N.V..
  - Action: terminated
  - Role: Chief Scientific Officer
  source text: On October 5, 2023, the Company announced that, effective October 4, 2023 (the “Effective Date”), Ricardo Dolmetsch terminated his employment with the Company as its Chief Scientific Officer for Good Reason
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590560/000110465923107209/0001104659-23-107209-index.htm
- Executive change
  Richard Porter changed role as Chief Business and Scientific Officer at uniQure N.V..
  - Action: designated
  - Role: Chief Business and Scientific Officer
  source text: the Board of Directors of the Company have designated Richard Porter, the Company’s current Chief Business Officer, to serve as the Company’s Chief Business and Scientific Officer, effective as of October 5, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590560/000110465923107209/0001104659-23-107209-index.htm
- Restructurings & Charges
  uniQure N.V. announced a restructuring with charges of approximately $2.3 million affecting global workforce and research operations (approximately 28% of the Company’s global workforce).
  - Type: restructuring
  - Charge: approximately $2.3 million
  - Affected area: global workforce and research operations
  - Headcount: approximately 28% of the Company’s global workforce
  source text: The Plan includes the discontinuation of more than half of the Company’s research and technology projects, the elimination of approximately 28% of the Company’s global workforce and the closure of a research lab in Lexington, MA. The Company estimates that it will incur charges of approximately $2.3 million in connection with the Plan, consisting primarily of cash expenditures related to employee severance costs.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590560/000110465923107209/0001104659-23-107209-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.